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Abstract: The peptide vaccine clinical trials encountered limited success because of difficulties 
associated with stability and delivery, resulting in inefficient antigen presentation and low 
response rates in patients with cancer. The purpose of this study was to develop a novel 
delivery approach for tumor antigenic peptides in order to elicit enhanced immune responses 
using poly(DL-lactide-co-glycolide) nanoparticles (PLGA-NPs) encapsulating tumor antigenic 
peptides. PLGA-NPs were made using the double emulsion-solvent evaporation method. 
Artificial antigen-presenting cells were generated by human dendritic cells (DCs) loaded with 
PLGA-NPs encapsulating tumor antigenic peptide(s). The efficiency of the antigen presentation 
was measured by interferon-γ ELISpot assay (Vector Laboratories, Burlingame, CA). Antigen-
specific cytotoxic T lymphocytes (CTLs) were generated and evaluated by CytoTox 96® 
Non-Radioactive Cytotoxicity Assay (Promega, Fitchburg, WI). The efficiency of the peptide 
delivery was compared between the methods of emulsification in incomplete Freund’s adjuvant 
and encapsulation in PLGA-NPs. Our results showed that most of the PLGA-NPs were from 
150 nm to 500 nm in diameter, and were negatively charged at pH 7.4 with a mean zeta potential 
of −15.53 ± 0.71 mV; the PLGA-NPs could be colocalized in human DCs in 30 minutes of 
incubation. Human DCs loaded with PLGA-NPs encapsulating peptide induced significantly 
stronger CTL cytotoxicity than those pulsed with free peptide, while human DCs loaded with 
PLGA-NPs encapsulating a three-peptide cocktail induced a significantly greater CTL response 
than those encapsulating a two-peptide cocktail. Most importantly, the peptide dose encapsulated 
in PLGA-NPs was 63 times less than that emulsified in incomplete Freund’s adjuvant, but it 
induced a more powerful CTL response in vivo. These results demonstrate that the delivery 
of peptides encapsulated in PLGA-NPs is a promising approach to induce effective antitumor 
CTL responses in vivo.
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Introduction
Tumor antigen-reactive T cells have been detected in the circulation of patients with 
cancer,1 evidencing the existence of a host immune response, which unfortunately 
fails to prevent disease progression in most cancer patients. It has been postulated 
that tumor-reactive T cells are in a nonresponsive state and low in number, and need 
to be activated to achieve an antitumor response.2 T lymphocytes recognize tumor 
antigens as small peptides of 8–10 amino acids in length, bound to cell surface mol-
ecules encoded by the major histocompatibility complex class I molecules. These 
major histocompatibility complex class I molecules are expressed in a number of cell 
types, including antigen-presenting cells (APCs). Dendritic cells (DCs) are widely 
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
1475
ORIGINAL RESEARCH
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/IJN.S29506International Journal of Nanomedicine 2012:7
distributed in peripheral tissues and lymphoid organs, they 
are believed to be the most potent APCs, and are specialized 
for the uptake of antigens, migration to lymph nodes, and 
activation of naïve T cells.3
In general, immunotherapy requiring an efficient 
T lymphocyte response is initiated by antigen delivery to 
APC.4 A large number of hydrophilic molecules are poorly 
taken up by cells since they do not efficiently cross the 
lipid bilayer of the plasma membrane. The low bioavail-
ability of peptides, proteins, and nucleic acids is due to 
many factors, including poor stability and susceptibility to 
enzymes.5 This is considered to be a major limitation for 
their use as therapeutic agents in biomedical research and 
the pharmaceutical industry. Cytoplasmic delivery is par-
ticularly important for immunotherapy, because cytosolic 
peptides are transported across the endoplasmic reticulum 
membrane with the help of the ATP-dependent transport-
ers associated with antigen processing.6 Peptides complexed 
with major histocompatibility complex class I molecules 
in the endoplasmic reticulum are then transported to the 
cell surface for recognition by cytotoxic T lymphocytes 
(CTLs).7 Peptide-based vaccines have been tested in clini-
cal trials but have encountered very limited success due to 
difficulties associated with stability and delivery, resulting 
in inefficient antigen presentation. The overall objective 
clinical response rate of peptide vaccine trials is in the range 
of only 4%–8%.8–10 In order to improve the efficiency of 
peptide-based vaccines, there is a significant need to design 
novel peptide delivery systems capable of inducing more 
effective tumor antigen-specific CTLs.
Nanoparticles (NPs) have been used as adjuvants11 
(added to a vaccine to augment immune responses toward 
  antigens). Although the adjuvanticity of NPs is not com-
pletely understood, it has been suggested that NPs can 
enhance antigen uptake and/or stimulate APCs.12 NPs 
have gradually garnered a global reputation as an effective 
delivery system for therapeutic agents since they can be 
designed to slip between intercellular spaces, enter cells, 
or transport directly through biological barriers to access 
targeted sites.13,14 NPs also encapsulate therapeutic agents 
offering potential protection from enzymatic degradation, 
metabolism, and filtration. Poly(DL-lactide-co-glycolide) 
(PLGA) is a copolymer that allows controlled release of 
drug over time or in response to a biological cue.15 PLGA 
has many advantages over other polymers used in drug and 
gene delivery including biodegradability, biocompatibility, 
and approval for human use granted by the US Food and 
Drug Administration (FDA).16
We have successfully delivered plasmid DNA,17–19 
drugs,13,19,20 and peptides21 by using PLGA-NPs in our pre-
vious work. In this report, we explore a novel strategy for 
effective peptide delivery that enhances the cytoplasmic 
delivery of peptides into DCs, eliciting a more robust tumor 
antigen-specific CTL response both in vitro and in vivo.
Materials and methods
Materials
Poly(D,L-lactide-co-glycolide) (PLGA, molecular weight 
23,000, copolymer ratio 50:50) was purchased from 
  Birmingham Polymers, Inc (Birmingham, AL). Polyvinyl 
alcohol (PVA, average molecular weight 30,000–70,000), 
trifluoroacetic acid, acetonitrile, lipopolysaccharide, and L-15 
(Leibovitz) medium were purchased from Sigma-Aldrich 
(St Louis, MO). Coumarin 6 was purchased from Polyscience, 
Inc (Warrington, PA). β2-Microglobulin was purchased from 
EMD Biosciences, (San Diego, CA). Human serum albumin 
was purchased from Instituto Grifols (Barcelona, Spain). 
Granulocyte-macrophage colony-stimulating factor, inter-
leukin (IL)-2, IL-4 and IL-7 were purchased from R and D 
(Minneapolis, MN). Monclonal human anti-interferon (IFN)-γ 
antibody was purchased from Mabtech (Cincinnati, OH). 
Hoechst 33342 was purchased from Invitrogen (Carlsbad, CA). 
CD8 MicroBeads were purchased from Miltenyi Biotec 
(Auburn, CA). All peptides used in this study were synthe-
sized by GenScript Corp (Piscataway, NJ). HLA-A2 (+) blood 
was purchased from San Diego Blood Bank and Scripps 
Green Hospital (San Diego, CA). T2, EL4 and transgenic 
adenocarcinoma of mouse prostate (TRAMP)-C2 cell lines 
were purchased from ATCC (Manassas, VA). Melanoma cell 
lines (624 and 1351) and TIL2080 (human tumor infiltrating 
lymphocyte) were kindly provided by Dr John R   Wunderlich 
(National Institutes of Health/National Cancer Institute, 
Bethesda, MD). ELISpot plates were purchased from Millipore 
(Billerica, MA). ELISpot substrate was purchased from Vector 
Laboratories (Burlingame, CA). Standard lactate dehydroge-
nase release assay was purchased from Promega (Madison, 
WI). All salts used in the preparation of buffers were from 
Fisher Scientific (Pittsburgh, PA). All aqueous solutions were 
prepared with distilled and deionized water (WaterPro Plus; 
Labconco, Kansas City, MO). C57BL/6 mice were purchased 
from Jackson Laboratory (Bar Harbor, ME).
Formulation and characterization  
of PLGA-NPs
NPs were formulated as previously described13 with minor 
modifications. In brief, 30 mg PLGA and 600 µg peptide 
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(melanoma antigen recognized by T-cells [MART]-1: 27–35, 
AAGIGILTV;22 gp100: 154–162, KTWGQYWQV;23 gp100: 
209–217, ITDQVPFSV;24 ovalbumin (OVA): 256–264, SIIN-
FEKL,25 and mouse six-transmembrane epithelial antigen of 
the prostate (mSTEAP): 326–335, DVSKINRTEM26) in 1 mL 
of chloroform was emulsified in 6 mL of 2% PVA to form 
an oil-in-water emulsion. The emulsification was carried out 
using a micro-tip probe ultrasonic sonicator set at 55 watts 
of energy output (XL 2015 Sonicator® ultrasonic processor; 
Misonix, Inc, Farmingdale, NY) for 2 minutes over an ice 
bath. The emulsion was stirred overnight on a magnetic stir 
plate to allow evaporation of chloroform and formation of 
PLGA-NPs. PLGA-NPs were recovered by ultracentrifuga-
tion at 30,000 rpm for 30 minutes at 4°C (Beckman   OptimaTM 
LE-80 K, Beckman Instruments, Palo Alto, CA), washed 
twice with sterile nano water to remove PVA and unencap-
sulated peptide, and then lyophilized for 48 hours (VirTis 
Company, Freeze Dryer, Gardiner, NY). To determine cellular 
uptake of PLGA-NPs, the formulation contained coumarin 6. 
The dye solution (50 µg of coumarin 6 in 50 µL chloroform) 
was added to the polymer solution prior to emulsification.
For measuring the size of the PLGA-NPs, samples were 
sputter coated with gold/palladium and imaged with a scan-
ning electron microscope (Phillips XL30, FEI, OR). Size 
distribution was analyzed using MetaMorph (Version 7.1.0.0, 
Molecular Devices Inc, Sunnyvale, CA). Zeta potential of the 
PLGA-NPs was measured using the Zetasizer® Nano ZS90 
(Malvern Instruments, Malvern, UK).
Determination of peptide loading  
by high-performance liquid 
chromatography (HPLC)
Peptides and peptide-loaded PLGA-NPs were identified 
using ultraviolet detection at 280 nm. Briefly, 50 µL of 
PLGA-NP suspension was injected into a Varian HPLC 
system (Varian, Walnut Creek, CA) equipped with a C18 
reverse phase column (8 × 100 mm, 15 µm particle size, 
pore size 300 A°) and a ultraviolet detector (Waters 486) 
set at 210 nm and a Gilson autoinjector (Mandel Scientific, 
Guelph, ON, Canada). The mobile phases employed were 
10% ACN in water with 0.1% trifluoroacetic acid (Solvent 
A) and 70% ACN in water with 0.085% trifluoroacetic acid 
(Solvent B). The column was equilibrated with 75% A and 
25% B prior to each run. Samples were eluted on a linear 
gradient of 25% to 100% B over 12 minutes at a fixed flow 
rate of 0.8 ml/min. The amount of peptide in each sample 
was calculated using a standard curve generated with known 
concentrations of the peptide.
Generation of human DCs  
and intracellular uptake of PLGA-NPs
Human DCs were generated by using enriched CD14+ 
  monocytes from HLA-A2 (+) healthy donors purchased from 
San Diego Blood Bank and Scripps Green Hospital with the 
presence of granulocyte-macrophage colony-stimulating 
factor (1000 U/mL) and recombinant IL-4 (400 U/mL) for 
7 days to produce immature DC (imDCs). Human imDCs 
at 50,000/mL were incubated with PLGA-NPs in medium 
(100 µg/mL) in a 12-well plate for 30 minutes, respectively. 
Cells were then washed with cold phosphate buffered saline 
(PBS) to remove uninternalized PLGA-NPs. Cell nuclei were 
stained with trihydrochloride (Hoechst 33342; Invitrogen, 
Carlsbad, CA) and washed with PBS before subjected to 
fluorescence-activated cell sorting analysis and imaging by 
a confocal microscope (Leica TCS SP2; Leica Microsystems 
Inc, Buffalo Grove, IL).
Antigen presentation by human mature 
DCs (mDCs) loaded with PLGA-NPs 
encapsulating MART-1
Human imDCs at day 7 were incubated with control PLGA-
NPs (empty-NPs), or PLGA-NPs encapsulating MART-1 
peptide for 1 hour, followed by the addition of lipopolysac-
charide for maturation. Mature DCs (mDCs) pulsed with 
MART-1 (5 µg/mL) served as the positive control. Test and 
control mDCs were cultured with TIL2080 cells at a ratio of 
1:1 for 20 hours. The efficiency of the antigen presentation 
was measured by IFN-γ ELISpot assay.
ELISpot assay
To test whether human mDCs loaded with PLGA-NPs 
  encapsulating MART-1 present antigens more efficiently to 
T cells than do MART-1 peptide-pulsed human mDCs, IFN-γ 
ELISpot assay was performed. Briefly, 96-well ELISpot 
plates were coated with 10 µg/mL monoclonal human anti-
IFN-γ antibody (Mabtech) at 4°C overnight. The plates 
were then blocked with 10% human AB serum (Omega 
Scientific, Tarzana, CA) for 2 hours at 37°C. Human mDCs 
(2 × 104) loaded with PLGA-NPs encapsulating MART-1 and 
MART-1 peptide-pulsed human mDCs (100 ng/mL) were 
incubated with TIL2080 cells, which recognize MART-1 
peptide, at a ratio of 1:1 in CTL medium in the ELIspot 
plates at 37°C for 20 hours. All cultures were carried out 
in triplicate. The plates were developed using 100 µL/well 
of substrate solution. Spots on the membrane were counted 
using automated image analysis system (CTL Analyzers 
LLC, Cleveland, OH).
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Generation of tumor antigen-specific CTLs
Human mDCs loaded with PLGA-NPs encapsulating pep-
tides were used as the APCs. In brief, NP-loaded DCs were 
added to enriched CD8+ cells derived from HLA-A2 (+) 
donors at a ratio of 1 to 10 in CTL medium (RPMI 1640 with 
10% human AB serum). IL-2 (20 U/mL) and IL-7 (30 U/
mL) were added 3 days later. Restimulation was first carried 
out on day 7 as follows: β2-microglobulin (5 µg/mL) and 
corresponding peptides (5 µg/mL) were added to irradiated 
autologous CD8− cells and incubated for 2 hours at 37°C. 
Four milliliters of L-15 (Leibovitz) medium containing 1% 
human serum albumin, β2-microglobulin and peptide was 
added to the adherent cells and incubated for 1.5 hours at 
25°C. Effector cells were added at 2 × 106 cells/mL in fresh 
CTL medium. The second restimulation was carried out on 
day 14. On day 21 tumor antigen-specific CTLs were tested 
by ELISpot and   cytotoxicity assay (CytoTox 96® Non-Radio-
active   Cytotoxicity Assay [Promega, Fitchburg, WI]).
Cytotoxic assay
T2 cells pulsed with corresponding   peptides and melanoma 
cells were used as target cells to test peptide-specific CTLs. 
EL4 pulsed with OVA, or mSTEAP peptide and TRAMP-
C2 cells were used as target cells to test the immune response 
elicited by vaccination of PLGA-NPs encapsulating peptide 
and peptide emulsified in incomplete Freund’s adjuvant 
(IFA). For cellular cytotoxicity assays, a standard lactate 
dehydrogenase release assay was performed according to the 
manufacturer’s instructions. In brief, 2 × 104 target cells were 
added to the peptides-specific CTLs at the ratios of 1:12.5, 
1:25, and 1:50 in a final volume of 100 µL. The plates were 
incubated for 3 hours and 15 minutes at 37°C after spin down. 
Ten microliters of 10× lysis buffer was added into the wells 
for maximum release, and incubation continued for 45 min-
utes at 37°C. Fifty microliters of supernatant was transferred 
to a fresh ELISA plate after spin down and 50 µL substrate 
was added to each well and mixed, and the plate was sealed. 
The mixture was incubated for 30 minutes at room tempera-
ture in the dark, and 50 µL stop solution was added to each 
well. The plate was read at 490 nm and the specific lysis was 
calculated by the following formula: %   Cytotoxicity = 100 × 
(  Experiment – Effector Spontaneous – Target Spontaneous)/
(Target Maximum – Target Spontaneous).27
In vivo distribution of PLGA-NPs  
after intraperitoneal (IP) injection
Coumarin  6-loaded  PLGA-NPs  were  injected  into 
C57BL/6 mice at 500 µg in 500 µL PBS by IP injection. 
The mice were sacrificed 30 minutes after injection and 
imaged using the Olympus OV100 imaging system (Olympus 
Corp, Shinjuku-ku, Japan).
Comparison of peptide delivery  
efficiency in vivo
Peptide delivery efficiency was measured in vivo using 
mSTEAP (a mouse peptide with 80% homology to human 
STEAP28) and OVA peptide as test and positive control pep-
tides, respectively. For free peptide immunization, 100 µg of 
mSTEAP or OVA was emulsified in IFA and delivered via 
subcutaneous (SC) injection. IP injection was performed for 
empty-NP- and peptide- (both OVA and mSTEAP) loaded 
PLGA-NPs.
Thirty-five male C57BL/6 mice were randomized into the 
following five groups: (1) Control NP (empty-NP), (2) OVA 
emulsified in IFA (OVA + IFA), (3) mSTEAP emulsified 
in IFA (mSTEAP + IFA), (4) PLGA-NPs encapsulating 
OVA, and (5) PLGA-NPs encapsulating mSTEAP. All mice 
were immunized once on day 0 (Table 1). Ten days after 
immunization, three mice in each group were sacrificed fol-
lowed by in vivo restimulation of splenocytes with the same 
peptides used for priming. Cytolytic activity of the CTLs 
was assayed 6 days after restimulation27 using a standard 
cytotoxic assay with the following targets: (1) EL-4 cells; (2) 
EL-4 cells pulsed with OVA peptide; (3) EL-4 cells pulsed 
with mSTEAP peptide; and (4) TRAMP-C2 cells.
Tumor size in immunized mice  
after challenge
Four C57BL/6 mice immunized in each group were chal-
lenged with 1 × 106 of TRAMP-C2 on day 10 via SC 
Table 1 Vaccination of C57BL/6 mice in different groups
Mice groups Vaccination Routes  
of injection
1.  Empty-NPs 500 µg empty-NPs  
in 500 µL of PBS
IP
2.  OVA + IFA 100 µg OVA peptide  
in IFA of 100 µL
SC
3.  OVA + NPs 500 µg PLGA-NPs-OVA  
in PBS of 500 µL
IP
4.  mSTEAP + IFA 100 µg mSTEAP peptide  
in IFA of 100 µL
SC
5.  mSTEAP + NPs 500 µg PLGA-NPs-mSTEAP  
in PBS of 500 µL
IP
Abbreviations: NPs, nanoparticles; PBS, phosphate-buffered saline; IP, intraperitoneal 
injection;  OVA,  ovalbumin;  IFA,  incomplete  Freund’s  adjuvant;  SC,  subcutaneous 
injection; PLGA, poly(DL-lactide-co-glycolide); mSTEAP, mouse six-transmembrane 
epithelial antigen of the prostate.
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injection in the right flank, and tumor size was monitored 
with a digital caliper (Thermo Fisher Scientific, Pittsburgh, 
PA) every 3 days.
Statistical analysis
P-values were calculated to test the statistical significance 
between the groups of free peptides and PLGA-NPs encapsu-
lating peptides using two-tailed unpaired Student’s t-test. The 
confidence interval was set at 95% and a P value of <0.05 was 
accepted as significant (*); P , 0.01 (**), P , 0.001 (***).
Results
Characterization of peptide-loaded 
PLGA-NPs
NPs are colloidal systems with a size range typically from 
1 to 1000 nm in diameter. They are formulated from a poly-
mer, in which the therapeutic agents were entrapped in the 
polymer matrix. The double emulsion-solvent technique is 
the most commonly used method to formulate polylactic acid 
(PLA) and PLGA NPs, with PVA to stabilize the   emulsion. 
PLGA-NPs were sputter coated with gold/palladium 
and imaged using a scanning electron microscope under 
20 kV (Figure 1A) and 10 kV (Figure 1B), respectively. The 
unfractionated PLGA-NPs demonstrated a size distribution 
range from 70 nm to 795 nm, and 78% of these PLGA-NPs 
are from 150 nm to 500 nm in diameter (Figure 1C). The 
PLGA-NPs were negatively charged at pH 7.4 with a mean 
zeta potential of –15.53 ± 0.71 mV (Figure 1D, n = 3), and 
the polydispersity index (PDI) is 0.308 ± 0.034 (n = 3) when 
analyzed by Zetasizer Nano ZS90. The size and potential of 
the PLGA-NPs used in this study varied slightly between 
batches, and also varied according to the different peptide(s) 
encapsulated. MART-1 and gp100:154–162 peptide-loaded 
PLGA-NPs are the representatives, which were used in the 
characterization of the PLGA-NPs in Figure 1.
Peptide loading and encapsulation  
in PLGA-NPs
Controlling both the drug-loading efficiency and particle 
size of the drug-loaded NPs is very important when using 
NPs as drug delivery systems.29 To measure the peptide 
loading and encapsulation efficiency, we defined peptide 
loading as the peptide present (µg) in 1 mg PLGA-NPs, 
and the encapsulation efficiency stands for the percentage 
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Figure 1 Characterization of PLGA-NPs. Images were taken by a scanning electron microscope (Phillips XL 30, FEI, OR). (A) Under 20 kV (40,000×). (B) under 10 kV 
(128,000×). (C) Size range of unfractionated PLGA-NPs. (D) Zeta potential of PLGA-NPs.
Abbreviation: PLGA-NPs, poly(DL-lactide-co-glycolide) nanoparticles.
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of peptide entrapped in PLGA-NPs over the initial amount 
of loaded peptide. Based on these definitions and the 
HPLC-analyzed results, the PLGA-NP peptide loading is 
3.176 ± 0.144 µg (n = 3), and the peptide encapsulation 
efficiency (%) is 82.34% ± 8.4% (n = 3).
Cellular uptake of PLGA-NPs  
in human DCs
Next, we studied whether the NP-loaded DCs could present 
the antigenic peptides to T cells more efficiently, leading to 
the induction of antigen-specific CTLs for immunotherapy. 
Coumarin 6 loaded PLGA-NPs were incubated with human 
imDCs for 1 hour and cell nuclei were stained with Hoechst 
33342. Images were taken under a confocal microscope, 
as shown in Figure 2A (4′,6-diamidino-2-phenylindole 
channel), Figure 2B (fluorescein isothiocyanate channel), 
Figure 2C (both 4′,6-d  iamidino-2-phenylindole and fluo-
rescein isothiocyanate channels overlaid), and Figure 2D 
(4′,6-  diamidino-  2-phenylindole, fluorescein isothiocya-
nate, and reflection channels   overlaid). Fluorescent sig-
nals were seen in the cytoplasm of human imDCs. To test 
uptake efficiency, human imDCs were next incubated 
with coumarin 6-loaded PLGA-NPs for 30 minutes, and 
washed twice with Hank’s buffered salt solution to remove 
uninternalized PLGA-NPs for fluorescence-activated cell 
sorting analysis. The result showed that 100% of human 
DCs were fluorescent positive (Figure 2E).
Antigen presentation comparison 
between human mDCs loaded  
with PLGA-NPs encapsulating peptide 
and those pulsed with free peptide
MART-1 peptide is the most well characterized and most 
commonly used epitope in melanoma studies, and is the 
target of tumor-infiltrating lymphocytes.30 TIL2080 cell line 
was used as effector cells to recognize and kill human mDCs 
loaded with PLGA-NPs encapsulating MART-1, or MART-1 
peptide-pulsed human mDCs while being the target cells. The 
results showed that human mDCs loaded with PLGA-NPs 
encapsulating MART-1 presented more MART-1 peptides 
to TIL2080 cells than those pulsed with MART-1 peptide, 
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Figure 2 Colocalization of poly(DL-lactide-co-glycolide) nanoparticles in human dendritic cells. Images were taken under a confocal microscope. (A) 4′,6-Diamidino-2-
phenylindole channel. (B) Fluorescein isothiocyanate channel. (C) 4′,6-Diamidino-2-phenylindole and fluorescein isothiocyanate channels overlaid. (D) 4′,6-Diamidino-2-
phenylindole, fluorescein isothiocyanate, and reflection channels overlaid. (E) Fluorescence-activated cell sorting analysis result.
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resulted in more release of IFNγ, as measured by ELISpot 
assay (Figure 3A, P = 0.0003).
Comparison of CTL cytotoxic activities
The cytototoxic activity of tumor antigen-specific CTLs 
generated by using both human mDCs loaded with PLGA-
NPs encapsulating MART-1 and human mDCs pulsed with 
MART-1 peptide were tested using cytotoxic assays. All the 
CTLs generated using the above methods killed both T2 cells 
pulsed with MART-1 (Figure 3B) and melanoma 624 cells 
(Figure 3C). The results demonstrated that the cytototoxic 
activity of the tumor antigen-specific CTLs generated by 
human mDCs loaded with PLGA-NPs encapsulating MART-1 
peptide (CTL/mDC + NP-MART-1) was significantly greater 
than that generated by human mDCs pulsed with free peptide 
(CTL/mDC + MART-1) when the ratio of effector/target was 
both 50/1 and 25/1 (Figure 3B and C). The cytototoxic activity 
of CTL/mDC + NP-MART-1 was still significantly stronger 
than CTL/mDC-MART-1 when the ratio of effector/target 
was 12.5/1 while the targets were MART-1-pulsed T2 cells 
(Figure 3B), along with targets that were melanoma 624 cells 
(Figure 3C). However, these CTLs could not recognize and 
kill T2 cells and 1351 melanoma cells due to lack of MART-1 
antigen expression on their cell surfaces (data not shown).
Most interestingly, the CTLs induced by human mDCs 
loaded with PLGA-NPs encapsulating a three-peptide 
cocktail (3P, including MART-1:27–35, gp100:154–162 and 
gp100: 209–217) generated significantly more robust cyto-
toxic activity than those encapsulating a two-peptide cocktail 
(2P, including MART-1:27–35 and gp100:154–162) when the 
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Figure 3 Enhanced antigen presentation and cytotoxic T lymphocyte (CTL) activity comparison. (A) ELISpot assay to test interferon-γ release when human mature dendritic 
cells presented melanoma antigen recognized by T-cell (MART)-1 peptide to TIL2080 cells. (B) CTL activity comparison between the CTLs generated by human mature 
dendritic cells loaded with NPs encapsulating MART-1 peptide and free MART-1 peptide-pulsed human mature dendritic cells when the target cells were T2 cells pulsed 
with MART-1 peptide. (C) CTL activity comparison when the target cells were melanoma 624 cells. (D) Cytotoxic activity comparison of the CTLs generated by poly 
(DL-lactide-co-glycolide nanoparticles encapsulating the two-peptide (MART-1:27–35 and gp100:154–162) and three-peptide (MART-1:27–35, gp100:154–162, and gp100: 
209–217) cocktails.
Notes: The confidence interval was set at 95% and a P value of ,0.05 was accepted as significant; **P , 0.01, ***P , 0.001.
Abbreviations: CTL, cytotoxic T lymphocyte; PLGA-NPs, poly(DL-lactide-co-glycolide) nanoparticles; hmDC, human mature dendritic cells.
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targets were melanoma 624 cells and T2 cells pulsed with 
the peptide-cocktails at any effector/target ratio (Figure 3D, 
P , 0.01). These CTLs are not able to recognize and kill 
1351 melanoma cells and T2 cells owing to lack of antigen 
expression on their cell surfaces (Figure 3D).
Distribution of the PLGA-NPs in vivo 
after IP injection
The three main types of professional APCs are macrophages, 
DCs, and B cells. Macrophages are predominantly located 
in the lungs, liver, neural tissue, bone, and spleen; imDCs 
are mostly located in the epithelium of the skin, the gastro-
intestinal tract and the respiratory tract. Most of the B cells 
are located in bone marrow and spleen. Thus, these organs 
were chosen for the biodistribution study. Fluorescent signals 
were compared between the blank control mouse and the 
mouse dosed with 500 µg coumarin 6-loaded PLGA-NPs 
30 minutes after IP injection. Scattered fluorescent particles 
were seen under the skin all over the mouse body, and these 
signals were also seen in the kidney, brain, pancreas, spleen, 
heart, lung, and liver (  Figure 4B), but were not seen in the 
blank control mouse, apart from autofluorescence in the paws 
and intestine (  Figure 4A). Enlarged images clearly showed 
that the fluorescent PLGA-NPs are distributed to various 
organs, including the intestine, brain, lung, and pancreas 
(Figure 4C).
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Kidney Pancreas
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Whole Mouse Whole Mouse
Heart Lung
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Figure 4 Distribution of poly(DL-lactide-co-glycolide) nanoparticles in vivo after intraperitoneal injection. (A) Blank control mouse. (B) Test mouse dosed with 500 µg 
poly(DL-lactide-co-glycolide) nanoparticles (PLGA-NPs) 30 minutes after intraperitoneal injection. (C) High-power mouse organ images. Coumarin 6-loaded poly(DL-lactide-
co-glycolide) nanoparticles were injected into C57BL/6 mice at 500 µg in 500 µL phosphate-buffered saline by intraperitoneal injection. 
Note: The mice were sacrificed 30 minutes after injection and imaged using the Olympus OV100 imaging system (Olympus Corp, Shinjuku-ku, Japan).
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Tumor suppression in mice immunized 
with PLGA-NPs encapsulating mSTEAP 
peptide
Based on observation records, tumor size measurement, and 
statistical data, delayed tumor development was observed in 
mice immunized with PLGA-NPs encapsulating mSTEAP 
peptide, and the tumor size was significantly smaller than 
in those in the control group immunized with empty-NP 
(P = 0.019, Figure 5A). The difference in tumor size between 
the mice immunized with mSTEAP peptide emulsified in 
IFA and PBS was not significant (P = 0.361, Figure 5A). 
Tumor size difference between the mice immunized with 
PLGA-NPs encapsulating mSTEAP peptide and those 
immunized with mSTEAP peptide emulsified in IFA did not 
reach significance, but there was a trend to smaller tumor 
size (P = 0.123) in the former.
PLGA-NPs encapsulating peptides 
induce a significantly stronger antitumor 
response
We next sought to address the question of whether PLGA-
NPs encapsulating peptides can be taken up by   professional 
APCs (DCs, macrophages, and B cells) in vivo, which can 
then present the loaded peptides to T cells, and eventually 
induce an effective immune response. To answer this, 35 male 
C57BL/6 mice were immunized with their   corresponding 
agents only once followed by in vitro restimulation of spleno-
cytes with the same peptides used for priming. We evaluated 
the lysis patterns of each agent on target cells. The results 
showed that mouse CTLs derived from the mice immunized 
with empty-NPs, if pulsed with SIINFEKL peptide (OVA, 
5 µg/mL) in vitro, were able to recognize and kill EL4 cells 
pulsed with OVA (♦ in Figure 5B).
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Figure 5 Immunization with PLGA-NPs encapsulating mSTEAP peptide elicited stronger immune response. (A) Tumor suppression was observed in the mice immunized 
with PLGA-NPs encapsulating mouse six-transmembrane epithelial antigen of the prostate (mSTEAP) peptide (•) when compared with mSTEAP peptide emulsified in 
incomplete Freund’s adjuvant (○). (B) Ovalbumin (OVA)-specific CTLs derived from the mice immunized with PLGA-NPs encapsulating OVA lysed a significantly higher 
percentage of EL4 cells pulsed with OVA than those immunized with OVA emulsified in IFA (■ vs ○). The CTLs derived from the mice immunized with empty-NP against 
EL4 cells pulsed with OVA (♦). Mice immunized with PLGA-NPs encapsulating mSTEAP peptide induced a more effective immune response, not only lysed significantly higher 
percentages of EL4 cells pulsed with mSTEAP peptide (C), but transgenic adenocarcinoma of mouse prostate-C2 cells than those derived from the mice immunized with 
mSTEAP emulsified in incomplete Freund’s adjuvant (D).
Abbreviation: PLGA-NPs, poly(DL-lactide-co-glycolide) nanoparticles.
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CTL activity in the mice immunized with PLGA-NPs 
encapsulating peptides was significantly higher than in those 
immunized with peptides emulsified in IFA. The difference in 
CTL activity between the groups of OVA + PLGA-NPs and 
OVA + IFA was 68.76% vs 55.19% (P = 0.0007), 53.25% vs 
39.05% (P = 0.0185) and 34.58% vs 20.74% (P = 0.0110) 
when the effector/target ratio was 50/1, 25/1 and 12.5/1, 
respectively, while the target cells were EL4 cells pulsed 
with OVA peptide (Figure 5B).
We also compared the CTL activity between the groups 
of mSTEAP + PLGA-NPs and mSTEAP + IFA; the differ-
ence was 62.19% vs 41.81% (P = 0.025), 48.07% vs 23.91% 
(P = 0.017), and 23.6% vs 14.85% (P = 0.019) when the effec-
tor/target ratio was 50/1, 25/1 and 12.5/1, respectively, while 
the target cells were EL4 cells pulsed with mSTEAP peptide 
(Figure 5C). When the target cells were TRAMP-C2 cells, 
the difference in CTL activity was 66.12% vs 36.41% 
(P = 0.003), 54.07% vs 23.79% (P = 0.007), and 31.73% vs 
13.35% (P = 0.003) while the effector/target ratio was 50/1, 
25/1 and 12.5/1, respectively (Figure 5D).
Most importantly, the peptide dose encapsulated in 
PLGA-NPs was 63 times less than that emulsified in IFA, but 
it induced a more robust CTL response. The lysis capacity 
of the CTLs induced by PLGA-NPs encapsulating mSTEAP 
peptide was 1.82–2.22-fold higher when the   effector/tar-
get ratio was 12.5/1 to 50/1 than of the CTLs induced by 
mSTEAP peptide emulsified in IFA while the targets were 
TRAMP-C2 cells.
Discussion
The successful generation of an effective immune response 
against tumor cells is a prerequisite for any immunotherapeu-
tic strategy for cancer.31 Boosting the immune system with 
tailored immunotherapies provides a promising alternative 
to standard chemo- and radiotherapy and will ideally yield a 
specific anticancer response with fewer side effects.32 In the 
field of cancer immunotherapy, most enthusiasm has been 
directed to the use of cancer vaccines.8 Peptide-based vac-
cines are more attractive than other forms including whole 
cell vaccines, protein vaccines, and DNA-based vaccines. 
However, one difficulty for peptide-based vaccines is their 
rather poor immunogenicity,33 thus, appropriate adjuvants 
are greatly needed to make them more potent in eliciting 
effective T cell responses.
IFA serves as a conventional carrier for peptide delivery, 
yet the response rate of peptide emulsified in IFA trials 
in 246 individuals was only 3.66%.8 To improve cancer 
prevention and treatment, specific immune-activating 
strategies must be investigated. Adjuvants are usually 
pharmacological or immunological agents which modify 
the effect of other agents (eg, drugs or vaccines) while 
having few, if any, direct effects when given alone. For 
standard prophylactic immunization in healthy individu-
als, only adjuvants that induce minimal side effects will 
prove to be acceptable. Adjuvants for cancer vaccines, 
nevertheless, need to be very potent, which may increase 
their toxicity and the induction of autoimmune reactions.34 
Particulate vaccine carriers offer a good balance between 
adjuvanticity and safety. In this study, we demonstrated 
that peptide-loaded PLGA-NPs mediated efficient peptide 
delivery to APC and induced tumor antigen-specific CTLs 
and effective prophylactic immune responses in vivo.
Particulate adjuvants have comparable dimensions to the 
pathogens recognized by the immune system (,5 µm), which 
offers a great advantage in vaccine technology.35 Particles are 
internalized by APCs via different mechanisms, depending 
on their size.36 Particles of 20–200 nm are usually taken 
up via endocytosis by DCs, while those of 0.5–5 µm are 
primarily taken up by macrophages via macropinocytosis or 
phagocytosis.32 We demonstrated by fluorescence-activated 
cell sorting that PLGA-NPs could be taken up by 100% of 
human DCs within 30 minutes after incubation. Importantly, 
more effective tumor antigen-specific CTLs were induced 
by using human DCs loaded with PLGA-NPs encapsulating 
peptide than human DCs pulsed with free peptide.
From our study of the distribution of PLGA-NPs after IP 
injection, we found that fluorescent PLGA-NPs are present 
in various organs, including the liver, spleen, brain, lung, 
etc (Figure 4B and C). It was reported that PLGA NPs 
of 105 nm were present in the blood at higher concentra-
tions for up to 24 hours and were able to reduce their uptake 
by the reticuloendothelial system, compared with that of 
etoposide-loaded PLGA NPs of 160 nm and pure drug.37 
For therapeutic targeting, PLGA-NPs should evade the 
reticuloendothelial system to achieve highest drug delivery 
efficiency. For example, PLGA-NPs of size 100 nm can be 
used for long-term circulation without the need for surface 
modification,38 and the nanocarriers must be hidden from 
the reticuloendothelial system because it could destroy any 
foreign material through opsonization, followed by phago-
cytosis by macrophages.39,40 The most important finding 
of our study is the in vivo targeting of the APCs, which 
could phagocytize the antigen-loaded PLGA-NPs after IP 
administration and present the antigens to naïve T cells for 
generating an effective immune response. Interestingly, we 
found that PLGA-NPs cross the blood–brain barrier (BBB) 
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in our study; another group also reported that the PLGA-
NPs were concentrated mainly in the hippocampus.41 The 
mechanism might be taking advantage of the leaky vessel 
walls by passive diffusion or convection, dependent on the 
hydrostatic and osmotic pressure differences between blood 
and interstitial space.
Among different polymers, PLGA and PLA have been 
extensively used as NP carriers in controlled-release deliv-
ery systems for many bioactive molecules due to their low 
toxicity, good bioavailability and biocompatibility, and FDA 
approval status. The bioactive molecules delivered include 
drugs,13,42–44 proteins,45,46 DNA,47–49 and oligonucleotides.50–52 
Only a few studies have shown peptide delivery by PLGA-
NPs to elicit a type 1 T helper immune response.53–55 We 
used the same PLGA polymer and double emulsion-solvent 
evaporation method, but a different protocol and with 
entrapped peptides, thus producing PLGA-NPs products 
with different characteristics including size, potential and 
polydispersity, etc. In other studies, particle size ranged 
from 1 to 10 µm,56 350 to 410 nm,55 and 290 to 350 nm57 
in   diameter. Encapsulation efficiency was 23% for OVA 
peptide56, 5.2% ± 0.6% for TRP2,55 and 67.3% ± 6.9% for 
7-acyl lipid A,55 and the peptide loading was 0.03 µg for OVA 
peptide,56 0.94 ± 0.11 µg for TRP2,55 and 1.79 ± 0.18 µg for 
7-acyl lipid A,55 respectively. Our results showed a size range 
for unfractionated PLGA-NPs from 70 nm to 795 nm; 78% 
of these PLGA-NPs sized from 150 nm to 500 nm in diam-
eter. Based on HPLC-analyzed results, our peptide loading 
was 3.176 ± 0.144 µg (n = 3), and the peptide encapsula-
tion efficiency was 82.34% ± 8.4% (n = 3). Our data are 
consistent with above results, but the peptide loading and 
encapsulation efficiency of our PLGA-NP products was 
much higher than that of other authors. These differences 
may be due to a more optimized delivery system because we 
found the PLGA-NPs, which were loaded with more pep-
tide (1 mg/batch), did not function better than those loaded 
with less peptide (600 µg/batch, data not shown).
For tumor antigen-specific CTL induction, Hamdy et al 
utilized C57BL/6 mice immunized SC with 10 µg tyrosinase-
related protein-2 (TRP2) encapsulated in PLGA-NPs, versus 
mice who received 10 mg plain PLGA-NPs (empty-NPs) 
SC on day 0, and boosted on day 11.55 Their results showed 
activated TRP2-specific CD8+ T cell responses in the drain-
ing lymph nodes and spleen of mice immunized with PLGA-
NPs encapsulating TRP2.55
In our study, the mice were immunized only once with 
500 µg PLGA-NPs encapsulating 1.588 µg mSTEAP pep-
tide, 500 µg control PLGA-NPs by IP injection, or 100 µg 
mSTEAP peptide emulsified in 100 µL IFA by SC injection. 
Most importantly, the peptide dose encapsulated in PLGA-
NPs was 63 times less than that emulsified in IFA, but it 
induced more robust CTLs with the lysis rate of 66.12% vs 
36.41%; 55.075% vs 24.795%, and 31.73% vs 14.85% when 
the target cells were TRAMP-C2 cells, and the effector/target 
ratio was 50/1, 25/1, and 12.5/1, respectively (Figure 5D). 
We found that tumors in the mice immunized with PLGA-
NPs encapsulating mSTEAP developed later and were 
significantly smaller than tumors in the mice immunized 
with mSTEAP + IFA (P = 0.019). CTL activity in the mice 
immunized with PLGA-NPs encapsulating peptide was 
much higher than that in the mice immunized with peptide 
emulsified in IFA.
Antigen presentation is a crucial step in the initiation of 
an effective immune response. DCs have a unique ability to 
efficiently present antigens and thus play a central role in the 
orchestration of the adaptive immune response. This has made 
these cells a major focus of interest in the conception of immu-
notherapeutic vaccine strategies. An immunization   strategy 
using PLGA-NPs encapsulating antigenic peptides is an 
efficient approach for antigen presentation that induces more 
effective tumor antigen-specific immune responses than free 
peptide emulsified in IFA. These findings provide a good 
rationale for using PLGA-NPs as competent carriers for future 
peptide-based cancer vaccine formulations.
Conclusion
The majority of the PLGA-NPs made in this study mea-
sured from 150 nm to 500 nm in diameter, and the mean 
zeta potential was –15.53 mV . The PLGA-NPs were able to 
be colocalized in human DCs within 30 minutes of incuba-
tion. As the APCs, human DCs loaded with PLGA-NPs 
encapsulating peptide induced a significantly stronger CTL 
cytotoxicity than those pulsed with free peptide in vitro. 
Much higher efficiency of peptide delivery (63 times) was 
found in PLGA-NPs when compared with IFA. PLGA-NPs, 
as a peptide carrier, induce a more powerful CTL response 
in vivo. These findings are fundamental for the development 
of peptide vaccines, and the induction of an effective immune 
response for cancer immunotherapy.
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